Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tempus AI, Inc. Class A (TEM)
:TEM
Holding TEM?
Track your performance easily
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.63Same Quarter Last Year
Moderate Buy
Based on 9 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: -29.80%
|Next Earnings Date:Aug 06, 2024
Earnings Call Sentiment|Positive
Tempus reported a strong quarter with significant revenue growth and strategic expansion through the acquisition of Ambry Genetics. Despite a negative EBITDA, the company showed improvement and is on track towards profitability. Certain challenges remain, such as sustaining high growth in the data business and improving sales force productivity.Company Guidance
During the Tempus AI Q3 2024 earnings call, the company reported a 33% revenue growth, reaching $180.9 million, with Genomics unit growth accelerating to 23.9%. Their data and services revenue saw a 64.4% year-over-year increase, driven by a significant 86.6% growth in the data licensing business. Adjusted EBITDA improved by $14.4 million year-over-year, resulting in negative $21.8 million. Tempus announced the acquisition of Ambry Genetics for $600 million, structured as $375 million in cash and $225 million in equity, with Ambry's business growing above 25% and generating significant EBITDA. The acquisition aims to enhance Tempus' synergies and accelerate its path to profitability.Strong Revenue Growth
Tempus reported a 33% revenue growth, reaching $180.9 million for the quarter.
Genomics Unit Growth
Genomics unit growth accelerated to 23.9% and the overall business grew by 20%.
Data and Services Revenue Surge
Data and services revenue grew 64.4% year-over-year, with data licensing business growth at 86.6%.
EBITDA Improvement
Adjusted EBITDA improved by $14.4 million year-over-year to negative $21.8 million.
Acquisition of Ambry Genetics
Tempus announced the acquisition of Ambry Genetics for $600 million, a strategic move to enhance hereditary screening capabilities.
---
TEM Earnings History
Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release | Slides | Play Transcript |
|---|---|---|---|---|---|---|---|
| Aug 06, 2024 | 2024 (Q2) | ― | ― | ||||
| Nov 04, 2024 | 2024 (Q3) | ― | ― | ||||
| Aug 12, 2025 | 2025 (Q2) | -0.63 | ― | ― | ― |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TEM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $49.50 | $44.50 | -10.10% |
| Aug 06, 2024 | $40.65 | $38.82 | -4.50% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Tempus AI, Inc. Class A (TEM) report earnings?
Tempus AI, Inc. Class A (TEM) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Tempus AI, Inc. Class A (TEM) earnings time?
Tempus AI, Inc. Class A (TEM) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TEM EPS forecast?
Currently, no data Available
---